Measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in acute myeloid
Lulu Wang1, Haixia Fu1, Yazhen Qin1
1Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China; National Clinical Research Center for Hematologic Disease, Beijing, China; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing.
Abstract:
KMT2A partial tandem duplication (KMT2A-PTD) is a recurrent genetic alteration in acute myeloid leukemia (AML), but its role as a measurable residual disease (MRD) marker before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unclear. We retrospectively analyzed 180 KMT2A-PTD AML patients undergoing allo-HSCT at Peking University People's Hospital between 2015 and 2025. Pre-transplant KMT2A-PTD MRD was quantified by real-time quantitative PCR, with positivity defined as ≥1500 copies/10⁵ ABL1. Among 158 patients transplanted in complete remission (CR), 144 had pre-transplant MRD assessment, and 34 (24%) were MRDpositive. Compared with MRD-negative patients, MRD-positive patients had significantly inferior 3- year overall survival (OS, 49% vs. 80%; p.
